MedTrace Logo

Regeneron 1331 Kinetics Sub-Study HoFH

NCT04722068 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2021-05-17

No results posted yet for this study

Summary

To evaluate the lipoprotein kinetics of subjects enrolled in the R1500-CL-1331 clinical trial (NCT02265952) to assess the mechanism by which the evinacumab may affect lipid levels in HoFH subjects.

Conditions

  • Hypercholesterolemia, Familial

Interventions

OTHER

Kinetics test

Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.

Sponsors & Collaborators

Principal Investigators

  • Marina Cuchel, MD, PhD · University of Pennsylvania

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-07
Primary Completion
2016-11-30
Completion
2021-01-01

Countries

  • United States
  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04722068 on ClinicalTrials.gov